Advanced search
Publication Cover
Journal of Medical Economics Volume 16, 2013 - Issue 4
Submit an article Journal homepage
1,273
Views
15
CrossRef citations to date
0
Altmetric
Commentary

Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis

David W. BrandesHope MS Center, Knoxville, TN, USA and UCLA, Los Angeles CAUSA
, MS, MD,
Karina RaimundoNovartis Pharmaceuticals Corporation East Hanover, NJUSA
, MS,
Neetu AgashivalaNovartis Pharmaceuticals Corporation East Hanover, NJUSACorrespondence[email protected]
, MS &
Edward KimNovartis Pharmaceuticals Corporation East Hanover, NJUSA
, MD, MBA
Pages 547-551 | Accepted 05 Feb 2013, Published online: 21 Feb 2013

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
R Brett McQueen, Kavita V Nair, Timothy L Vollmer & Jonathan D Campbell. (2015) Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 869-872.
Read now
Radu Tanasescu & Cris S Constantinescu. (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 621-630.
Read now
Josep Darbà, Lisette Kaskens & Rainel Sánchez-de la Rosa. (2014) Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Journal of Medical Economics 17:3, pages 215-222.
Read now

Articles from other publishers (11)

Yazed AlRuthia, Bander Balkhi, Sahar Abdullah Alkhalifah, Salman Aljarallah, Lama Almutairi, Miteb Alanazi, Abdulmalik Alajlan, Suliman M. Aldhafiri & Nuha M. Alkhawajah. (2021) Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia. International Journal of Environmental Research and Public Health 18:24, pages 13261.
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Maryam S. Alowayesh, Samar F. Ahmed, Jasem Al-Hashel & Raed Alroughani. (2019) Economic burden of multiple sclerosis on Kuwait health care system. PLOS ONE 14:5, pages e0216646.
Crossref
Sen Lin. 2019. The Science and Regulations of Naturally Derived Complex Drugs. The Science and Regulations of Naturally Derived Complex Drugs 271 295 .
Alexander Rae-Grant, Gregory S. Day, Ruth Ann Marrie, Alejandro Rabinstein, Bruce A.C. Cree, Gary S. Gronseth, Michael Haboubi, June Halper, Jonathan P. Hosey, David E. Jones, Robert Lisak, Daniel Pelletier, Sonja Potrebic, Cynthia Sitcov, Rick Sommers, Julie Stachowiak, Thomas S.D. Getchius, Shannon A. Merillat & Tamara Pringsheim. (2018) Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 90:17, pages 777-788.
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Matthew Reaney, Colleen A. McHorney, Bradley Curtis, Anna Rydén, Olivier Chassany & Chad Gwaltney. (2017) Using Individual Experiences With Experimental Medications to Predict Medication-Taking Behavior Postauthorization: A DIA Study Endpoints Workstream. Therapeutic Innovation & Regulatory Science 51:4, pages 404-415.
Crossref
Irene Cortese & Avindra Nath. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology 713 736 .
Stefan Braune, M. Lang & A. Bergmann. (2015) Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. Journal of Neurology 263:2, pages 327-333.
Crossref
R. Alroughani, S.F. Ahmed, R. Behbehani & J. Al-Hashel. (2014) Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. Clinical Neurology and Neurosurgery 119, pages 17-20.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.